Group 1: Cannabis Industry Impact - Cannabis stocks experienced a significant rally following President Trump's endorsement of cannabidiol (CBD) for senior healthcare, suggesting a potential shift in public perception and market dynamics [3][4] - Leading cannabis companies such as Tilray Brands, Canopy Growth, Cronos Group, and Aurora Cannabis saw substantial stock price increases, with Tilray Brands rising as much as 60% and Canopy Growth gaining approximately 17% [4][5] - The video posted by Trump emphasized CBD's benefits, including pain relief and improved sleep, and highlighted potential cost savings of $64 billion annually if cannabis is fully integrated into the healthcare system [6] Group 2: McDonald's Loyalty Program - McDonald's is reintroducing its popular Monopoly game to attract customers to its loyalty program, which currently accounts for about 25% of its U.S. business [10][12] - The new game format allows customers to scan game pieces from food packages into an app, offering prizes such as airline miles and cash, aiming to increase global active loyalty members to 250 million by the end of 2027 [11][12]

Core Insights - Tilray Medical is expanding its Tilray Craft portfolio in Germany with five new cannabis flower products produced at its EU-GMP certified facility in Neumünster, reflecting its commitment to providing diverse, quality medical cannabis options for patients [1][2][3] Company Overview - Tilray Medical is dedicated to transforming lives by providing safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Craft, and has established itself as a leading supplier of medical cannabis [5] - The company has evolved from being one of the first licensed producers of medical cannabis in Canada to building GMP-certified production facilities in Portugal and Germany [5] Product Details - The new Tilray Craft products are available by prescription at pharmacies throughout Germany, showcasing the company's dedication to advancing medical cannabis innovation and supporting healthcare professionals [3] - Tilray Craft focuses on high potency flower, cultivated indoors in Neumünster, with an emphasis on precision and quality control to ensure reliable medical cannabis for patients [4] Commitment to Quality - The production process at Tilray's facility adheres to rigorous quality control standards, ensuring that the medical cannabis provided is consistent and dependable for patient needs [2][4] - The company prioritizes patient care and aims to deliver consistent, quality solutions to physicians and pharmacies, placing patients' needs first [2]

Core Viewpoint - Tilray (TLRY) shares experienced a significant increase of nearly 60% following President Trump's endorsement of cannabidiol (CBD) as a transformative element in senior healthcare, suggesting potential for substantial medical cost savings of up to $64 billion annually [1][4]. Group 1: Stock Performance - Following the rally, Tilray stock reached a new 52-week high of $1.86 [2]. - Options data indicates heightened volatility for Tilray shares, with traders anticipating a 23.43% price movement by the end of the week, suggesting a trading range of $1.42 to $2.28 [5]. - Longer-dated options expiring on December 19 suggest an even wider range of $0.93 to $2.77, reflecting both optimism and risk [6]. Group 2: Regulatory Impact - The potential rescheduling of marijuana from Schedule I to Schedule III could significantly alter the cannabis industry, allowing access to traditional banking services and more favorable tax treatment [3]. - Trump's support for Medicare coverage of marijuana-related treatments indicates a shift towards federal backing for the CBD industry, which could alleviate criminal penalties and financial restrictions [4]. Group 3: Market Sentiment - The market sentiment appears to be leaning towards the upside, driven by Trump's remarks and speculation regarding federal marijuana rescheduling [5][6]. - Wall Street analysts recommend maintaining a long-term position in Tilray shares, indicating confidence in the company's future prospects [7].

Stock Market Overview - U.S. stocks advanced, with the Nasdaq rising 107 points (0.48%) to 22,591.15, S&P 500 up 0.26% to 6,661.21, and Dow Jones increasing 0.15% to 46,316.07 [1] Wolfspeed Inc. (NYSE: WOLF) - Wolfspeed's stock surged by 1,726.45%, closing at $22.10, with an intraday high of $22.10 and a low of $8.05; it reached a 52-week high of $22.10 and a low of $0.39 [2] - The surge followed the announcement of a reorganization plan under Chapter 11 bankruptcy, which will reduce debt by 70% and cut interest payments by 60% [3] Tilray Brands, Inc. (NASDAQ: TLRY) - Tilray's shares increased by 60.87%, closing at $1.85, with a high of $1.86 and a low of $1.34; the stock's 52-week high and low are $1.86 and $0.35, respectively [4] Robinhood Markets Inc. (NASDAQ: HOOD) - Robinhood's stock rose 12.27%, closing at $136.72, with an intraday high of $136.84 and a low of $123.78; it achieved a new all-time high of $136.84, with a 52-week low of $22.05 [5][6] - The rally followed the CEO's announcement that event contracts on the platform topped four billion, with half traded in the third quarter alone, and a strong August report showing assets surged 112% year-over-year to $304 billion [6] Etsy - Etsy's shares climbed 15.83%, closing at $74.34, with a high of $75.77 and a low of $63.64; the stock's 52-week high and low are $75.77 and $40.05, respectively [6] - The increase was driven by OpenAI's unveiling of the "Buy it in ChatGPT" feature, allowing users to purchase directly from Etsy sellers [7] MoonLake Immunotherapeutics (NASDAQ: MLTX) - MoonLake's stock plummeted by 89.93%, closing at $6.24, with a high of $7.14 and a low of $5.95; the stock's 52-week high is $62.75, with a low of $5.95 [8] - The decline occurred despite positive results from MoonLake's Phase 3 VELA trial, which showed statistically significant HiSCR75 responses in patients with moderate to severe hidradenitis suppurativa [8]

Market Performance - Market indexes experienced gains, with the Dow up +68 points, S&P 500 gaining +17 points, and Nasdaq increasing +107 points, while the Russell 2000 rose +2 points [2] - The market was influenced by a government shutdown threat and OPEC+'s decision to raise oil production by 137K barrels per day, leading to a -3.8% drop in WTI prices and a -2.5% decline in Exxon Mobil and BP stocks [1] Housing Market - Pending Home Sales rose by +4.0% in August, surpassing expectations and reversing a previous downward trend, aided by slightly easing mortgage rates [3] - Newly-built homes also saw an increase, with homebuilder stocks like Lennar, Pulte Home, and KB Home rising more than +1% due to pent-up demand [4] Cannabis Industry - The Trump administration is considering reclassifying cannabis from Schedule I to Schedule III, which could have significant implications for the industry, resulting in a +60% increase in Tilray's stock price [5] Economic Data Expectations - Upcoming economic data includes Case-Shiller Home Prices, Chicago Business Barometer, and Consumer Confidence, with expectations for slight increases and a narrowing in Consumer Confidence to 95.8 [6] - The Job Openings and Labor Turnover Survey (JOLTS) is expected to show a decrease in job openings to 7.1 million, the lowest since September 2024 [7] Company Earnings - Nike is set to report fiscal Q1 earnings, with expectations of a -60% year-over-year earnings decline and -4.95% revenue drop, despite having outperformed earnings expectations for eight consecutive quarters [8][9]

Core Insights - Shares of cannabis and CBD-related companies surged following US President Trump's comments on the potential of hemp-derived CBD in healthcare and the exploration of reclassifying marijuana under federal law [1][2] Market Reaction - Tilray Brands (TLRY) increased by approximately 42%, Canopy Growth (WEED) rose by around 18%, Cronos Group gained about 15.5%, and Aurora Cannabis saw a 25% rise, with cannabis-focused ETFs like MSOS and Roundhill climbing approximately 21% each [2] Implications for ASX Cannabis/Hemp/CBD Stocks - The US regulatory environment often influences sentiment and capital flows in the broader cannabis sector, which could benefit ASX cannabis and CBD stocks [3] - Potential benefits for ASX cannabis/CBD/hemp stocks include sentiment and capital flow spillover, licensing and export opportunities, valuation re-rating, and increased M&A interest [3][5] - Companies to watch include Little Green Pharma (ASX: LGP), Botanix Pharmaceuticals (ASX: BOT), Vitura Health (ASX: VIT), and Cann Group (ASX: CAN), each with unique positions in the market [4][5] Global Investor Interest - A positive regulatory shift in the US could attract global investor interest in the cannabis sector, including Australian companies [5] - ASX-listed CBD/hemp companies may experience increased inflows from global funds, and if US regulatory risks diminish, Australian producers could find more partners or export markets [5] - The potential for re-ratings of ASX CBD/hemp stocks exists as multiples may expand due to a more favorable US outlook [5]

Market Overview - U.S. equity markets showed a mixed but generally positive performance on September 29, 2025, with major indexes closing higher despite concerns over a potential government shutdown [1][2] - The Nasdaq Composite led gains, rising between 0.5% and 0.8%, while the S&P 500 increased by 0.3% to 0.6%, and the Dow Jones Industrial Average edged up by 0.1% to 0.2% [2] Economic Indicators - The U.S. dollar index (DXY) decreased by 0.2% to 97.94, and the 10-year Treasury yield fell to 4.14% from approximately 4.19% [3] - Gold prices rose over 1% to a record high of $3,860 per ounce, indicating investor anxiety and expectations for continued Federal Reserve rate cuts [3] - West Texas Intermediate (WTI) crude oil futures dropped nearly 4% to about $63.20 per barrel due to reports of an OPEC output hike [3] Upcoming Events - A federal government shutdown is imminent, with a deadline set for October 1, 2025, which could lead to increased market volatility [4] - Key economic data releases are expected, including September's Nonfarm Payrolls and Unemployment Rate reports, with economists predicting an addition of 51,000 jobs and an unemployment rate of 4.3% [5] Federal Reserve Insights - Expectations for further interest rate cuts in 2025 remain, with traders pricing in approximately 40 basis points of easing by year-end [6] Company News - Electronic Arts (EA) shares surged over 5% after announcing a $55 billion all-cash deal to go private, although analysts downgraded the stock to "neutral" [8] - Nvidia (NVDA) rose 2.1%, benefiting from new deals with OpenAI, Alibaba, and Microsoft, while Intel (INTC) shares declined nearly 3% after a significant surge the previous week [9] - CSX (CSX) climbed 3.5% following a CEO change, and Carnival (CCL) reported strong fiscal third-quarter earnings, raising its full-year income outlook [10] - Western Digital (WDC) and Seagate (STX) saw significant gains, with Western Digital up over 9% and Seagate about 5% [11] - Energy stocks underperformed, with Exxon Mobil (XOM) and Chevron (CVX) dropping 2.4% and 2.5%, respectively, due to falling crude prices [12] - Marijuana-related stocks surged, with Tilray Brands (TLRY) and Canopy Growth (CGC) rising by 36.5% and 11.7% respectively, following positive remarks from President Trump [12] Earnings Reports - Upcoming earnings reports include Jefferies Financial Group Inc. (JEF), expected to report an EPS of $0.79, and Progress Software Corporation (PRGS), anticipated to report an EPS of $1.02 [13]

Core Insights - Cannabis stocks experienced a significant surge following Donald Trump's video promoting cannabis use for seniors and Medicaid coverage for CBD products [1][2] - The video, produced by the Commonwealth Project, highlights the potential benefits of hemp-derived CBD as a pain and stress reliever for seniors [1][2] - The cannabis industry is advocating for federal decriminalization to enhance research investment and broaden access to medical cannabis [6] Industry Impact - Stocks for major cannabis companies, including Canopy Growth, Tilray, and Cronos Group, saw substantial increases, with Tilray rising over 40% after the video release [2][6] - The AdvisorShares Cannabis ETF (MSOS) also experienced a notable rise on the same day [2] - The video emphasizes the need for educating healthcare providers and providing Medicare coverage for CBD, which could significantly impact the market [3] Regulatory Context - Under the Biden administration, there have been requests to the DEA to reclassify cannabis as a lower-risk substance, which is currently classified as Schedule I [4][5] - The Trump administration had previously been silent on cannabis decriminalization but indicated a willingness to consider reclassification [5] - Currently, 40 states permit medical cannabis use, while 24 states allow non-medical use, indicating a growing acceptance at the state level [5] Challenges and Opportunities - The Commonwealth Project notes that the current Schedule I classification complicates research and integration of cannabis into medical care, limiting access for seniors [7] - There is uncertainty regarding the stance of Terrance Cole, Trump's DEA administrator, on cannabis reclassification, as his focus has been on other priorities [7]

Industry Overview - The cannabis industry is experiencing a positive shift following President Trump's endorsement of cannabidiol (CBD) for senior healthcare, leading to a rally in cannabis shares [1][2] - The U.S.-listed shares of Canadian cannabis companies are seeing significant gains, indicating a strong market reaction [1] Political Influence - Trump's statement on CBD as a potential alternative to traditional prescription drugs may provide momentum for the cannabis industry, which has faced strict regulations [2][3] - The possibility of reclassifying marijuana under federal law could alleviate operational and tax challenges for cannabis businesses, although it would not equate to full legalization [2][3] Market Performance - Analysts highlight that political backing, even if symbolic, is crucial for an industry struggling with regulatory hurdles [3] - The global cannabis market is projected to reach a value of $444.34 billion by 2030, showcasing its high growth potential despite volatility [4] Stock Performance - Notable stock performance includes: - Tilray Brands (TLRY) up 41.3% - Aurora Cannabis (ACB) up 23.6% - Canopy Growth (CGC) up 15.7% - Green Thumb Industries (GTBIF) up 15.7% - Curaleaf Holdings (CURLF) up 20% - Trulieve Cannabis (TCNNF) up 12.7% [5]

And a post last night on Truth Social, President Trump shared a video highlighting the health benefits of hemp hemp derived cannabid oil or CBD. Now, Tillray, Canopy Growth, Aurora, all jumping double digits. The video said it could quote, "Revolutionize senior health care, serving as a alternative to costly prescription drugs." Of course, another area of the president's focus.Now, this isn't Trump's first move in cannabis, though. Back in the 2018 Farm Bill, hemp derived products like CBD were legalized. A ...